DK1663141T3 - Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin - Google Patents

Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin

Info

Publication number
DK1663141T3
DK1663141T3 DK04740995T DK04740995T DK1663141T3 DK 1663141 T3 DK1663141 T3 DK 1663141T3 DK 04740995 T DK04740995 T DK 04740995T DK 04740995 T DK04740995 T DK 04740995T DK 1663141 T3 DK1663141 T3 DK 1663141T3
Authority
DK
Denmark
Prior art keywords
xylometazoline
solution containing
aqueous pharmaceutical
pharmaceutical solution
oxymetazoline
Prior art date
Application number
DK04740995T
Other languages
Danish (da)
English (en)
Inventor
Frank Boehme
Bernd Eschenbach
Dagmar Faerber
Claudia Hey
Barbara Pfaff
Marion Tschaikin
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1663141(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1663141T3 publication Critical patent/DK1663141T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04740995T 2003-08-13 2004-07-14 Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin DK1663141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10337186A DE10337186A1 (de) 2003-08-13 2003-08-13 Wässrige Wirkstoff-Lösung
PCT/EP2004/007780 WO2005018601A1 (de) 2003-08-13 2004-07-14 Wässrige phramateuziche lösung enthaltend oxymetazolin und/oder xylometazolin

Publications (1)

Publication Number Publication Date
DK1663141T3 true DK1663141T3 (da) 2007-07-30

Family

ID=34201503

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04740995T DK1663141T3 (da) 2003-08-13 2004-07-14 Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin

Country Status (19)

Country Link
US (1) US20060222718A1 (pt)
EP (1) EP1663141B1 (pt)
JP (1) JP4750703B2 (pt)
KR (1) KR20060065677A (pt)
CN (1) CN100531733C (pt)
AT (1) ATE357212T1 (pt)
AU (1) AU2004266443A1 (pt)
BR (1) BRPI0413478A (pt)
CA (1) CA2535533C (pt)
CY (1) CY1107633T1 (pt)
DE (2) DE10337186A1 (pt)
DK (1) DK1663141T3 (pt)
ES (1) ES2282871T3 (pt)
MX (1) MXPA06001596A (pt)
PL (1) PL1663141T3 (pt)
PT (1) PT1663141E (pt)
RU (1) RU2343918C2 (pt)
WO (1) WO2005018601A1 (pt)
ZA (1) ZA200602071B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005075735A (ja) * 2003-08-28 2005-03-24 Rohto Pharmaceut Co Ltd オキシメタゾリン含有組成物
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101576539B (zh) * 2009-06-19 2012-05-23 广东省药品检验所 一种盐酸赛洛唑啉中杂质a的测定方法
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
DE102012005452A1 (de) 2011-12-30 2013-07-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
EA032719B1 (ru) 2014-12-24 2019-07-31 Ярдан-Галенски Лабораторий Д.Д. Назальная лекарственная форма против заложенности носа
BR112018072177A2 (pt) * 2016-05-17 2019-02-12 Proponent Biotech Gmbh composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
DE202017104738U1 (de) 2017-07-31 2018-08-01 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Zusammensetzung für die nasale Applikation
CN107362141B (zh) * 2017-08-16 2018-06-05 深圳大佛药业股份有限公司 一种盐酸羟甲唑啉鼻喷雾剂及其制备方法
CA3105449A1 (en) * 2018-07-02 2020-01-09 Bayer Healthcare Llc Stable pharmaceutical formulations of oxymetazoline
US10799481B1 (en) * 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
PL4404916T3 (pl) 2021-09-22 2025-12-08 Jadran - Galenski Laboratorij D.D. Ulepszona kompozycja farmaceutyczna do stosowania donosowego, jej wytwarzanie i stosowanie
CN117982422B (zh) * 2024-04-03 2024-07-26 深圳大佛药业股份有限公司 一种用于治疗鼻炎的喷雾剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
NZ505919A (en) * 1998-01-30 2002-10-25 Novartis Consumer Health S Nasal solutions
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
NL1011016C2 (nl) * 1999-01-13 2000-07-14 Dagra Pharma Bv Neusspray op basis van xylometazoline en kamille-extract.
WO2000078297A2 (de) * 1999-06-22 2000-12-28 Boehringer Ingelheim International Gmbh Stabile xylometazolin- und oxymetazolinlösung
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
RU2212235C1 (ru) * 2001-12-24 2003-09-20 Закрытое акционерное общество "Брынцалов-А" Капли назальные бризолин, обладающие сосудосуживающим, противовоспалительным и противоотечным действием

Also Published As

Publication number Publication date
AU2004266443A1 (en) 2005-03-03
CA2535533C (en) 2011-10-18
WO2005018601A1 (de) 2005-03-03
DE10337186A1 (de) 2005-03-17
PT1663141E (pt) 2007-06-27
JP2007501817A (ja) 2007-02-01
ES2282871T3 (es) 2007-10-16
ATE357212T1 (de) 2007-04-15
CY1107633T1 (el) 2013-03-13
PL1663141T3 (pl) 2007-07-31
CN1832726A (zh) 2006-09-13
KR20060065677A (ko) 2006-06-14
RU2006107446A (ru) 2007-09-20
CA2535533A1 (en) 2005-03-03
MXPA06001596A (es) 2006-05-19
DE502004003305D1 (de) 2007-05-03
JP4750703B2 (ja) 2011-08-17
CN100531733C (zh) 2009-08-26
RU2343918C2 (ru) 2009-01-20
US20060222718A1 (en) 2006-10-05
EP1663141B1 (de) 2007-03-21
EP1663141A1 (de) 2006-06-07
ZA200602071B (en) 2007-05-30
BRPI0413478A (pt) 2006-10-17

Similar Documents

Publication Publication Date Title
DK1663141T3 (da) Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin
NO20054018L (no) Intranasal formulering av rotigotin
CU23367A3 (es) Formulación de moxifloxacino con sal común
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
NZ597757A (en) Aqueous insulin preparations containing methionine
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
DE50310516D1 (de) Fredericamycin-derivate
AR035266A1 (es) Solucion desinfectante basada en hipoclorito sodico y procedimiento para su preparacion
GEP20084340B (en) Pharmaceutical compositions comprising fentanyl for intranasal delivery
PT1556371E (pt) Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
NO20022201L (no) Lösninger inneholdende Epinastin
NO20082727L (no) Salter av 9-oksoakridin-10-eddiksyre med 1-alkylamino-1-deoksypolyoler
BRPI0410758A (pt) composições, dispositivos e métodos para estabilizar o dióxido de halogênio e aumentar sua eficácia
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
ATE406871T1 (de) Konzentrierte wässrige ambroxollösung
NO20070250L (no) S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor
AU2001285944A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
NO20044769L (no) Behandling av smerte med ifendropil
CY1105105T1 (el) Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
NO20050163L (no) Mikrokapsler for den forsinkede og kontrollerte frigivelse av perindopril
FR2883702B1 (fr) Concentre emulsifiable contenant du 2',4'-difluoro-2-(alpha, alpha-trifluoro-m-tolyloxy)-nicotinanilide et composition aqueuse obtenue par dilution du concentre
RU2003117898A (ru) Способ местного лечения деструктивных форм неспецифических заболеваний легких, плевритов и эмпием плевральной полости
SE0401942D0 (sv) New antimicrobial peptide complexes
RU2000105080A (ru) Препарат для лечения гриппа